Undervisningen i Molecular drug development and pharmacology Forårssemesteret 2013

Transkript

1 Undervisningen i Molecular drug development and pharmacology Undervisere: Forårssemesteret 2013 Hold 1-3 Agnete Larsen (AL) Sted: Forelæsninger: Fysiologisk aud. A bygning 1162, lokale FYS A Benny Bang Andersen, Lundbeck (BBA) Biokemi 6 aud. bygning 1170, lokale 347Bio6 Betina Elfving (BEL) Lille anatomisk aud. bygning 1231, lok. 4Lille ANA Birgitte Brock (BB) Britt Elmedahl (BE) Holdtimer Bartholin 1, bygning 1241, lokale 135 Bart1 Casper Kierulf Lassen (CKL) Bartholin 2, bygning 1241, lokale 125 Bart2 Charlotte Uggehøj Andersen (CA) Bartholin 3, bygning 1241, lokale 119 Bart3 Christina Brock (CRB) Bartholin 4, bygning 1241, lokale 114 Bart4 Daniel Dupont (DD) Bartholin, bygning 1241, Læsesalen Læsesal Daniela Grimm (DG) Anatomi, bygning 1231, lokale 224 Ana224 Dorthe Bonnerup (DB) Anatomi, bygning 1231, lokale 228 Ana228 Egon Persson, Novo Nordisk (EP) Anatomi, bygning 1231, lokale 232 Ana232 Elise Røge Hedegaard (ERH) Store anatomisk aud. Bygning 1232, lok Ana115 Gregers Wegener (GW), Biokemi 1, bygning 1170, lokale 240 Bio1 Henrik Agersø, Novo Nordisk (HA) Biokemi 3, bygning 1170, lokale 248 Bio3 Henrik Dizel (HD) Biokemi 4, bygning 1170, lokale 340 Bio6 Jan Egebjerg (JE), Biofys, bygning 1182, lokale 319 Biofys1 Jørgen Rungby (JR) Kamille Smidt Rasmussen (KSR) Lab øvelser Øvelses-laboratoriet i Bartholin Bygningen Lars Peter Nielsen (LPN) Farmakologisk Institut Lars Rejnmark (LR) Lene Høimark (LH) Lisbeth Moreau Andersen (LMA) Lotte Bjerre Knudsen, Novo Nordisk (LBK) Lærke Egefjord (LE) Maja Simonsen (MS Michael Etzerodt (ME) Michael Gejl Jensen (MG) Michael Ploug, Rigshospitalet (MP Nico Liebenberg (NL) Nils Magnusson (NM) Peter Andreasen (PA) Sanne Bjørn Nygaard (SBN) Simon Comerma (SC) Simon Glerup (SG) Thao Phuong Tran (TT) Thomas Vorup-Jensen (TVJ) Torben Laursen (TL) Side 1 af 10

2 Torben Ørntoft (TØ) Trine Henriksen (TH) Troels Skrydstrup (TS) Forelæsninger med fed skrift, K=kollokvier, Pensum: i Principles of Pharmacology Noter til laboratorie øvelser Artikler gennemgået ved holdtimer Hold 1: Molekylær medicin 1, Hold 2: Molekylær medicin 2, Hold 3: Medicinal kemi Dato Kl Emne Lokale Hold Underviser Kap 28-jan Uge Introduction to molecular drug development and pharmacology Bio6 KSR Man 9-10 Drug targets I Pharmacology Bio6 JE Drug targets II Human Pharmacology Bio6 JE Drug absorption, distribution, metabolism and elimination Bio6 KSR Ons 30-jan Pharmacokinetics Bio6 KSR 3 Uge Drug targets II Human Pharmacology JE Drug targets II Human Pharmacology JE Drug targets II Human Pharmacology JE 1+2 Side 2 af 10

3 Uge 6 04-feb 8-9 Neurodegenerative diseases Bio6 JE Man 9-10 Antipsychotic drugs Bio6 GW Antidepressant drugs Bio6 GW Drug absorption, distribution, metabolism and elimination KSR Drug absorption, distribution, metabolism and elimination KSR Drug absorption, distribution, metabolism and elimination KSR feb Hydroxytrypamine and purines Bio6 NM 14 Ons 9-10 Adrenergic pharmacology and the automomic nervous system Bio6 AL 8+10 Uge Cholinergic transmission Bio6 AL Pharmacokinetics KSR Antipsychotic drugs NL Antidepressant drugs BEL Pharmacokinetics KSR Antipsychotic drugs NL Antidepressant drugs BEL Pharmacokinetics KSR Antipsychotic drugs NL Antidepressant drugs BEL Side 3 af 10

4 Dato Kl Emne Lokale Hold Underviser Uge 7 11-feb 9-10 Atherosclerosis and lipoprotein metabolism Bio6 MS 19 Man Analgesic drugs Bio6 DG Adrenergic pharmacology and the automomic nervous system SBN Adrenergic pharmacology and the automomic nervous system SBN Adrenergic pharmacology and the automomic nervous system SBN 8+10 Uge 7 13-feb 8-9 Pharmacology of volume regulation Bio6 US 20 Ons 9-10 Pharmacology of vascular tone Bio6 US K: Therapeutic proteins, FVIIa Bio6 EP Hydroxytrypamine and purines NM Analgesic drugs DG Hydroxytrypamine and purines NM Analgesic drugs DG Hydroxytrypamine and purines NM Analgesic drugs DG Uge 8 18-feb 8-9 Pharmacology of cardiac rhythm and contractility Bio6 US Man 9-10 Integrative cardiovascular pharmacology Bio6 US Pharmacology of volume regulation SC K: Therapeutic proteins, FVIIa PA Cholinergic transmission SBN Pharmacology of volume regulation SC K: Therapeutic proteins, FVIIa PA Cholinergic transmission SBN Cholinergic transmission SBN Pharmacology of volume regulation SC K: Therapeutic proteins, FVIIa PA Side 4 af 10

5 Uge 8 20-feb 8-9 Introduction til PK/PD Bio6 BB Ons 9-10 K: PK/PD modelling Bio6 HA K: PK/PD modelling Bio6 HA Neurodegenerative diseases JE Pharmacology of vascular tone ERH Atherosclerosis and lipoprotein metabolism TH Neurodegenerative diseases JE Pharmacology of vascular tone ERH Atherosclerosis and lipoprotein metabolism TH Neurodegenerative diseases JE Pharmacology of vascular tone ERH Atherosclerosis and lipoprotein metabolism TH 19 Dato Kl Emne Lokale Hold Uge 9 25-feb 8-9 Pharmacological treatment of diabetes Bio6 JR 30 Man 9-10 The reproductive system Bio6 CA K: Discovery and development of novel psychotropic drugs Bio6 BBA Pharmacology of cardiac rhythm and contractility SC Integrative cardiovascular pharmacology ERH Pharmacology of cardiac rhythm and contractility SC Integrative cardiovascular pharmacology ERH Pharmacology of cardiac rhythm and contractility SC Integrative cardiovascular pharmacology ERH 25 Side 5 af 10

6 9-10 The pituitary and the adrenal cortex Bio6 TL Ons 27-feb K: Monoclonal antibodies as drugs Bio6 HD Uge K: PK/PD modelling DB The reproductive system CA K: PK/PD modelling DB The reproductive system CA K: PK/PD modelling DB The reproductive system CA 29 Dato Kl Emne Lokale Hold Uge mar 8-9 Haemopoetic system and treatment of anaemia Bio6 MG 44 Man 9-10 Anticancer drugs Bio6 BE Bone metabolism Bio6 LR Pharmacological treatment of diabetes LE K: Monoclonal antibodies as drugs PA Pharmacological treatment of diabetes LE K: Monoclonal antibodies as drugs PA Pharmacological treatment of diabetes LE K: Monoclonal antibodies as drugs PA Dato Kl Emne Lokale Hold Ons 06-mar Uge Haemostasis and thrombosis Bio6 LH Local hormones, inflammation and immune reactions Bio6 LPN Clinical drug development Bio6 BB? Discovery and development of novel psychotropic drugs SG Anticancer drugs CKL Discovery and development of novel psychotropic drugs SG Anticancer drugs CKL Discovery and development of novel psychotropic drugs SG Anticancer drugs CKL Side 6 af 10

7 Uge 11 Man 11-mar 8-9 Bone metabolism TT Bone metabolism TT Bone metabolism TT Local hormones, inflammation and immune reactions LPN Haemopoetic system and treatment of anaemia MG Haemostasis and thrombosis Bio6 2 LH Local hormones, inflammation and immune reactions LPN Haemopoetic system and treatment of anaemia MG Haemostasis and thrombosis Bio6 1 LH Local hormones, inflammation and immune reactions LPN Haemopoetic system and treatment of anaemia MG Haemostasis and thrombosis Bio6 3 LH 22 Uge 11 Ons 13-mar The pituitary and the adrenal cortex TL The pituitary and the adrenal cortex TL The pituitary and the adrenal cortex TL Uge apr 9-10 K: Individualised thearapy. The role of genomics and bioinformatics Bio6 TØ ons K: Directed evolution of a human TNF-alpha antagonist Bio6 ME Dato Kl Emne Lokale Hold Uge apr Man 9-10 Respiratory system Bio6 LPN K:Nuclear receptors as drug targets Bio6 PA Side 7 af 10

8 Uge apr 8-9 Ons Protein Therapeutics Bio6 TVJ Respiratory system LPN K:Nuclear receptors as drugs PA Respiratory system LPN K:Nuclear receptors as drugs PA Respiratory system LPN K:Nuclear receptors as drugs PA Dato Kl Emne Lokale Hold Underviser Uge apr 8-9 Target identification and validation Bio6 JE Man 9-10 Target validation- follow up Bio6 TS K:GLP-1 modification and diabetes Bio6 LBK K:GLP-1 modification and diabetes Bio6 LBK Uge apr 9-10 Drug development chemical structures Bio6 TS Ons Anti- inflammatory and immunosupressant drug Bio6 AL Calculations II JE Calculations II JE Calculations II JE Dato Kl Emne Lokale Hold Underviser Uge apr 9-10 Sideeffects and safety/pharmacovigilance Bio6 LPN Man Anti- inflammatory and immunosupressant drug AL Anti- inflammatory and immunosupressant drug AL Anti- inflammatory and immunosupressant drug AL Uge apr Ons K:RNA aptamers as drugs Bio6 DD Uge 18 Man Dato Kl Emne Lokale Hold Underviser 29-apr K: Structure-based design of drugs and imaging reagents Bio6 MP 02-maj Ons Uge Introduction to local analgetics. Bio6 CB Kap. 11 Lab. exerc K: Structure-based design of drugs and imaging reagents PA K: Structure-based design of drugs and imaging reagents PA K: Structure-based design of drugs and imaging reagents PA Uge 19 Tidspunkt for praktiske øvelser kommer senere Side 8 af 10

9 Side 9 af 10

10 Side 10 af 10